Pam is a Member in the firm's Corporate & Securities Section. She concentrates on counseling the firm's public company clients with respect to securities compliance under both the Securities Act of 1933 and the Securities Exchange Act of 1934; executive compensation-related issues; and corporate governance matters, including compliance with the Sarbanes-Oxley Act of 2002 and the Dodd Frank Act of 2010. In addition, she advises and represents public and private companies, as well as individuals, on all aspects of equity compensation matters. Pam works with clients' management teams, boards, and compensation committees to develop and design appropriate executive compensation programs, and to resolve legal issues confronting employers when implementing and revising such programs.
Representative merger and acquisition transactions where Pam has provided executive compensation and securities counsel:
· Caliper Life Sciences, Inc. in its sale to PerkinElmer, Inc.
· Microfluidics International Corporation in its sale to IDEX Corporation
· Arbinet Corporation in its sale to Primus Telecommunications Group, Inc.
· Biocius Life Sciences Inc. in its sale to Agilent Technologies
· AMICAS, Inc. in its sale to Merge Healthcare
· Myriad Genetics, Inc. in its spin-off transaction which resulted in a new public company, Myriad Pharmaceuticals, Inc.
· Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its acquisition of ViroChem Pharma Inc.
· QIAGEN NV in its acquisition of Digene, Inc.
· eScription in its sale to Nuance Communications
Before joining Mintz Levin, Pam was an associate in the business practice group of another premier Boston-based law firm. She has advised venture capital fund clients and participated in the organization of venture capital funds. Pam has also handled corporate and securities law matters for a range of businesses, including entrepreneurial companies and private equity investors. She represented both corporations and investors in private placements, public offerings, mergers and acquisitions, and general corporate law matters.
Before attending law school, Pam worked as a corporate service representative for the Boston Trade Bank, from its inception as a start-up venture. In that capacity, she handled cash management products, and worked with clients to maximize short-term corporate funds.
Pam is admitted to practice in Massachusetts and is a member of the National Association of Stock Plan Professionals. She earned her certificate in French Studies from the University of Paris-Sorbonne (1985). Pam received her Bachelor of Commerce in finance and international business from McGill University (1986) and her J.D., cum laude, from Boston University School of Law (1991). She was honored as a Paul J. Liacos Distinguished Scholar, an Edward F. Hennessey Scholar, and a G. Joseph Tauro Scholar.
Recent Publications
· Co-author, "Weighing Stock Options In M&A Transactions," Law360 (June 22, 2011)
· "The Treatment of Stock Options in the Context of a Merger or Acquisition Transaction," VCExperts (December 2011)
· "The Treatment of Stock Options in the Context of a Merger or Acquisition Transaction," NASPP Advisor (September/October 2011)
Recent Speaking Engagements
· Speaker, "Recent Developments in Proxy Disclosure of Executive Compensation," Boston Bar Association (December 2010)
· Speaker, "General Equity Matters," High Technology Accounting Conference: A to Z of Equity Accounting presented by the Massachusetts CPA Society (June 2009)
Industries
Life Sciences
Telecommunications & Media